News

In this analysis, the differences in adverse events resulting from JAKi among adults and children were evaluated.

The Reagan Udall Foundation hosted a meeting on PTSD treatment needs, with experts and stakeholders highlighting gaps and potential therapies, including MDMA-assisted therapy.

Barratt reflects on recent therapeutic developments in IgAN, the most recent being the full FDA approval of sparsentan (Filspari), and the importance of preventing kidney failure.

These findings further endorse the need for health care quality improvements for veterans, given the rates of melanoma, skin cancer, and psoriasis.

A new study discovers patients with IBD who respond well to high-dose thiamine treatment have an abundance of faecalibacterium prausnitzii.

Findings support the use of FIB-4’s low cut-off for ruling out severe fibrosis and cirrhosis as well as the use of Forns index’s high cut-off for significant fibrosis in chronic HCV.

Participants in a study in China also experienced comparable safety and immunogenicity.

Host Veeral Sheth, MD is joined by John Sheets, PhD, the president, CEO, and co-founder of Pantheon Vision, an early research-stage organization working to develop bioengineered solutions to eliminate corneal blindness.

The FDA has granted full approval to sparsentan (Filspari) for slowing kidney function decline in adults with IgAN at risk of disease progression based on PROTECT trial data.

A study found high error rates in racial and ethnic designations in pediatric health records across 3 Michigan hospitals, risking misinformed care strategies.

The Delphi survey collected opinions from members of the European Alpha-1 Research Collaboration to guide the diagnosis, treatment, and management of severe AATD.

Vadadustat once-daily demonstrated noninferiority to darbepoetin alfa for the change in mean hemoglobin from baseline, while 3-times-weekly did not.

Deepak Bhatt, MD, MPH, MBA, discusses a group of 4 high-impact studies from ESC Congress 2024: FINEARTS-HF, ABYSS, RESHAPE-HF2, and SHAM-PVI.

In an interview with HCPLive, Wadden discussed the findings of a post-hoc analysis, supporting how semaglutide is not linked to an increased suicidal ideation risk.

The August 2024 month in review highlights our coverage of pipeline news, a cross-specialty feature about dialysis, and other recent renal news and research from the past few weeks.

The biosimilars month in review highlights recent data demonstrating clinical equivalence and efforts to improve their access.

Ahmad Masri, MD, MS, highlights a trio of studies from ESC Congress 2024 examining use of aficamten in hypertrophic cardiomyopathy.

A post-hoc analysis of the STEP trials found semaglutide for weight management doesn’t increase depression or suicidal thoughts in individuals without major mental disorders.

This August 2024 month in review spotlights HCPLive’s top coverage of hepatic pipeline news and recent research in liver disease, HCV, and more.

The FDA approved neffy for treating severe allergic reactions in people over 33 kg in August 2024.

This August 2024 month in review highlights new recommendations from the USPSTF, FDA approval of a treatment for chronic GVHD, and Phase 2 data for severe HDFN.

This Month in Review summarizes some of the most significant stories covered in the month of August in the pulmonary health space, including new research and FDA news.

Ahmad Masri, MD, MS, discusses the results of a SEQUOIA-HCM substudy leveraging cardiac magnetic resonance to assess structural changes associated with aficamten use in HCM.

This month in review highlights MDMA-assisted therapy coverage, experiences with zuranolone a year after its approval, and early positive data on potential treatments.

Rizk discusses the recent FDA accelerated approval of iptacopan (Fabhalta) and reflects on the significance of other therapeutic developments in IgAN.

This month in review highlights the top sleep stories in August, from sleep health in patients undergoing dialysis to the benefits of catching up on sleep.

Ahmad Masri, MD, MS, discusses an integrated safety analysis of aficamten using data from 3 clinical trials.

The decision to revoke the conditional marketing authorization is based on a June 2024 CHMP recommendation from the EMA suggesting the benefits of Ocaliva do not outweigh its risks.